Furthermore, a strong correlation between the potency of cancer therapeutics and Th1/Th2 cytokine ratio has been reported (Gadducci et al. 2004; Smyth et al. 2004; Katsikis et al. 1995). The gene discussed is NELFCD; the disease is cancer.